Press release 2015-10-16

C-RAD signs agreement with Yale-New Haven Hospital

Yale-New Haven Hospital (YNHH) in Connecticut, USA and C-RAD have signed a procurement agreement in which C-RAD receives a multi-site purchase order to supply Smilow Cancer Hospital and their satellite facilities with surface tracking technology. Yale-New Haven Hospital has placed orders for four surface tracking systems for radiation therapy – involving both Catalyst HD™ and Sentinel 4DCT™ products.

The first two C-RAD systems are already operational at Yale-New Haven Shoreline Medical Center in Guilford, Connecticut. The following installations of two systems will be at the Smilow Care Center in Hamden, CT. While the initial focus of the Catalyst in Guilford is to support patient positioning and respiratory gating for breast cancer patients, the surface tracking system in New Haven will also be utilized for high-precision real-time patient monitoring for stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS).

Prior to the agreement, Yale-New Haven evaluated several surface tracking systems.

C-RAD will use Yale-New Haven Hospital as a reference site and to perform clinical demonstrations of Sentinel 4DCT and Catalyst. Yale-New Haven will be part of C-RAD's Research Fellow Program and conduct joint research in the field of SRS.

The Catalyst™ and Sentinel™ systems offer the required technology to perform high-end treatment techniques within radiation therapy. With this solution C-RAD supports the whole 4D treatment chain from imaging to treatment delivery. Respiratory gated treatments are frequently used when the target volume is close to cardiac tissue or for special treatments in which the tumor position depends on the respiratory cycle.

"We expect further orders under this agreement to be placed over the coming months," says Tim Thurn, CEO of C-RAD. "We launched Catalyst HD systems last year specifically to support stereotactic treatments, which are enjoying a rapid growth specifically in the US market. Recent accomplishments have led to us having a reputation for the best solutions for breast cancer patients in Europe. We are now working on being recognized in the same way in North America."

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 39. C-RAD's business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established

three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are being integrated. C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit www.c-rad.com.

For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).